FDA Warns 30 Telehealth Firms Over Compounded GLP-1 Claims

FDA announced on 3 March 2026 that it issued 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. Separately, on 6 February 2026, FDA said it intended to take action against non-FDA-approved GLP-1 drugs by restricting GLP-1 APIs intended for mass-marketed compounded products.

For compliance teams, the larger point is that compounded GLP-1 promotion has become more than a commercial issue. It is now clearly an enforcement issue too. Inference: where public demand, marketing pressure, and unclear claims converge, regulatory scrutiny tends to intensify quickly.